Live
Endpoints NewsInside Makary’s ouster; Another win for Lilly’s triple-G; and more10x Genomics BlogSerge Saxonov (TXG) reports multiple 2026 sales and a 35,270-share RSU grant - Stock Titan10x Genomics BlogTXG (NASDAQ) Form 144: RSU grant 26,276 shares; insider sold 7,826 - Stock Titan10x Genomics NewsAdam Taich files to sell 32,648 shares | TXG SEC Filing - Form 144 - Stock TitanMerck & Co.Spotlight On: Five things to watch at ASCO - FirstWord PharmaNovo NordiskBiopharma bites: CHMP backs oral Wegovy, Retro's financing, plus CVC's bid for Recordati - FirstWord PharmaEndpoints NewsFDA clears Gilead's hepatitis D drug, four years after prior rejectionClinical OMICsFungal Adjuvant Mannadjuvant Extends mRNA COVID-19 Vaccine ProtectionsEndpoints NewsGOP lawmaker asks Trump administration to curb China biotech dealsClinical OMICsHow Colorectal Tumors Escape KRAS Inhibitors IdentifiedClinical OMICsFDA Approves Datroway as First-Line Therapy for Triple-Negative Breast CancerFDA News ReleasesFDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
Lonza News Feb 3, 2026

Deutsche Bank Maintains Buy on Lonza Group AG (LZAGY) Feb 2026 - Meyka

Deutsche Bank Maintains Buy on Lonza Group AG (LZAGY) Feb 2026 - Meyka

Original
Body unavailable. Use the original source.